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Background: Preservation of cardiac grafts for transplantation is not standardized and most
centers use a single administration of crystalloid solution at the time of harvesting. We
investigated possible benefits of an additional dose of cardioplegia dispensed immediately
before implantation.
Methods: Consecutive adult cardiac transplantations (2005–2012) were reviewed. Hearts
were harvested following a standard protocol (Celsior 2L, 4–8°C). In 2008, 100 ml crys-
talloid cardioplegic solution was added and administered immediately before implanta-
tion. Univariate and logistic regression analyses were used to investigate risk factors for
post-operative graft failure and mid-term outcome.
Results: A total of 81 patients, 44 standard (“Cardio−”) vs. 37 with additional cardiople-
gia (“Cardio+”) were analyzed. Recipients and donors were comparable in both groups.
Cardio+ patients demonstrated a reduced need for defibrillation (24 vs. 48%, p=0.03),
post-operative ratio of CK-MB/CK (10.1±3.9 vs. 13.3±4.2%, p=0.001), intubation time
(2.0±1.6 vs. 7.2±11.5 days, p=0.05), and ICU stay (3.9±2.1 vs. 8.5±7.8 days, p=0.001).
Actuarial survival was reduced when graft ischemic time was >180 min in Cardio− but not
in Cardio+ patients (p=0.033). Organ ischemic time >180 min (OR: 5.48, CI: 1.08–27.75),
donor female gender (OR: 5.84, CI: 1.13–33.01), and recipient/donor age >60 (OR: 6.33,
CI: 0.86–46.75), but not the additional cardioplegia or the observation period appeared
independent predictors of post-operative acute graft failure.
Conclusion: An additional dose of cardioplegia administered immediately before implan-
tation may be a simple way to improve early and late outcome of cardiac transplantation,
especially in situations of prolonged graft ischemia. A large, ideally multicentric, randomized
study is desirable to verify this preliminary observation.
Keywords: cardiac transplantation, cardioplegia, cardiac surgery outcome, organ
INTRODUCTION
Myocardial protection during harvesting, transport, and implan-
tation of cardiac grafts is obviously a critical determinant of post-
transplantation outcome. However, despite a significant improve-
ment in results of cardiac transplantation over the last decades, the
optimal preservation strategy has not yet been clearly defined. Sev-
eral perfusates have been proposed; the currently most commonly
used being the HTK (Bretschneider, Custodiol), the St-Thomas
(Plegisol), and the University of Wisconsin (Belzer) solutions, all
developed in the 70s, as well as the more recently developed Celsior
solution (1). None of them has clearly emerged as significantly bet-
ter than the other, thus leaving transplantation surgeons at liberty
to select or adapt their own preservation strategy (2–4).
In a few publications, authors have described, in their methods,
the adjunction of complementary doses of cardioplegic solutions
administered at the time of implantation (5, 6). However, these
various strategies have not been systematically evaluated (7).
Therefore in the current analysis, we aimed at exploring the
possible benefit of administrating an additional dose of cardio-
plegic solution just before starting with the implantation of the
graft in terms of myocardial protection and early and mid-term
post-operative outcomes.
MATERIALS AND METHODS
The study investigated a consecutive series of adult patients under-
going orthotopic cardiac transplantation at a tertiary referral car-
diac surgery unit in Switzerland between January 1st 2005 and
August 31st 2012. Patients were identified from a prospectively
maintained institutional registry (Intellect 1.6.5, Dendrite Clinical
Systems, Henley-on-Thames, UK). All patients provided informed
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consent for anonymized observational analyses of their data at
the time of surgery and the local ethical committee approved the
present investigation as part of our regular institutional quality
audit.
STUDY DESIGN AND OUTCOME MEASURES
Analytic strategy was agreed before data were inspected. The
main analysis focused on significant association between addi-
tional administration of a single dose of crystalloid cardioplegia
immediately before graft implantation and post-reperfusion signs
of myocardial damage (including the ratio of cardiac enzymes
CK-MB/CK and the rate of spontaneous return to sinus rhythm),
and post-operative clinically relevant in-hospital complications
[including acute graft failure, the development of multiple organ
failure (MOF), early mortality], and mid-term survival. We
defined acute graft failure as the need to implant an IABP, ECMO,
or an assist device (8). Support with any high-dose inotrope,
inodilator, vasopressor, and/or pulmonary vasodilator drug was
used as marker of insufficient cardiac output or tissue perfusion
despite fluid resuscitation.
Secondary analyses aimed at defining independent predictors
of post-operative acute graft failure.
SURGERY, MYOCARDIAL PROTECTION, AND ANESTHESIA
The surgical procurement and myocardial preservation protocol
were standardized, and included the infusion under low pressure
of 2000 ml cold (4–8°C) Celsior solution. Celsior solution was
used for cold storage and transport. Hearts implanted until August
2008 were not treated with a supplementary dose of cardioplegic
solution (group “Cardio−”). Starting August 2008, an additional
single antegrade coronary infusion of 100 ml cardioplegic solu-
tion (Cardioplexol™, Laboratorium Dr G. Bichsel AG, Unterseen,
Switzerland) was administered immediately before graft implanta-
tion (group “Cardio+”). Cardioplexol™ is a low-volume (100 ml)
crystalloid solution based on Kalium, Magnesium, Procaine, and
Xylitol, and which is injected (in approximately 15 s) directly
into the coronary arteries by the surgeon himself. Cardioplex-
ol™ is typically used for standard cardiac surgical procedures.
It is though to be directly injected into the aortic root by the
surgeon himself, and typically induces a cardiac arrest within 5–
8 s (9). Anesthetic protocol was standardized for all patients and
included the intraoperative use of fentanyl or sufentanil, isoflu-
rane, rocuronium, as well as propofol for post-operative seda-
tion. Orthotopic transplantation was performed under moder-
ate hypothermic cardiopulmonary bypass. Recipient cardiectomy
and if present removal of a previously implanted assist device
was performed timely with the availability of the donor heart.
Transplantation technique was standardized with a majority of
patients receiving bicaval anastomoses to prevent tricuspid valve
insufficiency and sinus node dysfunction in the long term. Dur-
ing weaning and post-CPB, adrenaline and milrinone were used
as first-line inotropic agents. Pulmonary vasodilation was rou-
tinely aimed for using inhaled nitric oxide, with inhaled iloprost
as a backup. Noradrenaline was added to correct low systemic
vascular resistance at high or normal cardiac output only. Aza-
thioprine (AZA) (5 mg/kg) was given immediately before surgery
and high-dose methylprednisolone (1000 mg) before reperfusion
in the operating theater and a immunosuppressive regime was
installed as follows: antithymocyte globulin (ATG) 4–5 mg/kg was
initiated as induction therapy within 12 h post-transplant and
continued for up to a maximum of five days tailored by CD3
cell count. All patients received a calcineurin inhibitor for early
post-operative immunosuppression and for maintenance treat-
ment in combination with prednisone (0.8 mg/kg/day tapered
to 0.15 mg/kg/day within 5 months) and AZA or mycophenolate
mofetil (MMF) (tacrolimus and MMF, replaced cyclosporine A
and AZA on January 1, 2007). In case of severe early post-operative
kidney dysfunction, CNI was tapered or replaced by a mammalian
target of rapamycin (mTOR) inhibitor.
DATA SOURCE, MANAGEMENT OF MISSING VALUES AND DEFINITIONS
All variables were available from our institutional registry, and
were completed with specific data from our ICU (intubation time,
ICU length of stay, post-operative inotropes, thoracic drainage)
as well as with follow-up information provided by our institu-
tional Heart Failure and Transplant Outpatient Unit. Prior to
analysis, data were scrutinized for completeness, plausibility, and
outliers. In case of missing or obviously incorrect values, alterna-
tive data sources such as hospital and ICU records were used for
data replication.
Post-operative new-onset renal insufficiency was defined by a
new need for dialysis or, in patients with preoperative creatinine
levels below 2 mg/dl (172µmol/l), if the post-operative creatinine
level was above 2 mg/dl and at least double the preoperative value.
STATISTICAL ANALYSIS
Continuous variables are summarized as mean± SD and median.
To avoid undue influence of skewed data, all comparisons of
continuous variables are based on non-parametric tests (Mann–
Whitney). Dichotomous variables are expressed in absolute num-
bers and percentages, and comparisons were made using a Chi
square test. Multivariable logistic regression modeling was used
to assess the influence of cardioplegia, adjusting for established
influence factors on acute graft failure such as ischemic time of
the heart before implantation, duration of aortic cross-clamping,
donor age more than 60 years, and gender of the donor. We sequen-
tially tested different models to avoid more than three independent
variables.
Kaplan–Meier curves of overall long-term survival are pre-
sented including 95% confidence intervals. Kaplan–Meier esti-
mates of cumulative probability of survival were calculated and
compared using log-rank statistics. We used Cox proportional
hazard models to compare the hazard ratios of patients with vs.
without additional cardioplegia, and with global cardiac ischemia
longer vs. shorter than 180 min, on overall mortality, including
interaction terms for cardioplegia and ischemic time.
Since the two groups were defined by two consecutive peri-
ods, we tested the possible influence of the year of transplantation
surgery on the incidence of post-operative acute graft failure in a
logistic regression analysis, as well as on overall mortality in a Cox
regression. No association was found and this parameter was thus
eliminated from further analysis.
Finally, a propensity analysis was performed using the age of the
donor, the ischemic time, and the logistic EuroSCORE to construct
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the propensity score. The inverse probability of treatment weight-
ing (IPTW) was included into the analyses. Tails were trimmed at
both ends of the distribution in both groups in areas of suspected
residual confounding.
All tests and confidence intervals are two-sided and P values
<0.05 are deemed to indicate statistically significant differences.
All statistical analysis was performed by a biostatistician (BG)
using Stata 12.0 (StataCorp, College Station, TX, USA).
RESULTS
COMPARISON OF RESULTS OBTAINED WITH OR WITHOUT ADDITIONAL
CARDIOPLEGIA
Eighty-one adult patients were transplanted during the observa-
tion period. Forty-four were operated between January 2005 and
August 2008 (group “Cardio−”) and did not receive an additional
dose of cardioplegia, as opposed to 37 patients operated between
August 2008 and August 2012 (group “Cardio+”) who did. Nine
surgeons performed between 2 and 18 transplantations (4.4± 2.2,
median: 5). Baseline characteristics of the study groups are sum-
marized in Table 1A. Corresponding donor characteristics and
operative data are presented in Tables 1B,C, respectively. Both
groups appear mostly similar except for the rate of previous car-
diac surgery, which was higher in the Cardio+ group (86 vs. 61%,
p= 0.011), and the rate of transplantation for which both the
recipient and donor were>60 years old (16 vs. 5%, p= 0.079) for
the Cardio+ and Cardio− groups, respectively (Tables 1A,B).
Immediate evolution after aortic declamping and myocar-
dial reperfusion was characterized by a higher rate of spon-
taneous sinus rhythm in the Cardio+ group (48 vs. 24%,
p= 0.030), as well as by a reduced CK-MB/CK ratio (10.1± 3.9
vs. 13.3± 4.2%, p= 0.001; Table 2A). Intubation time (2.0± 1.6
vs. 7.2± 11.5 days, p= 0.049), length of stay in ICU (3.9± 2.1 vs.
8.5± 7.8 days, p= 0.001) as well as the post-operative length of
stay in hospital (31.3± 16.4 vs. 56.5± 59.4 days, p= 0.020) were
shorter in the Cardio+ group (Table 2B).
MID-TERM SURVIVAL RATE
Since both groups were consecutive, follow-up was 28.8± 15.0
and 60.2± 32.3 months in the Cardio+ and the Cardio− groups
respectively. Survival rate at 1 and 3 years were improved in the
Cardio+ group although not statistically significant. However,
analysis of subgroups based on a graft ischemic time cut-off arbi-
trarily set at 180 min revealed a trend for an improved survival rate
in Cardio+ treated hearts previously exposed to graft ischemia
>180 min (Table 3). Actuarial survival curves drawn for these
four subgroups are displayed in Figure 1. Cardio− patients with
graft ischemia >180 min had a significantly decreased survival
rate (Cardio−, p= 0.033). Conversely, we found no association
between survival profile of Cardio+ patients and graft ischemic
time (Figure 1).
DETERMINATION OF INDEPENDENT PREDICTORS OF POST-OPERATIVE
ACUTE GRAFT FAILURE
Immediate graft failure after reperfusion occurred in nine
patients, requiring implantation of a VAD (Impella Recover,
n= 1), veno-arterial ECMO (Medos-Deltastream, n= 6), and/or
an IABP (n= 5). A univariate analysis (see Appendix) fol-
lowed by a multiple logistic regression analysis identified three
donor/recipient-related independent predictors (graft ischemic
time; both recipient and donor age >60 years; female gender;
Tables 4A and 5). Operative times were also significantly increased
in this group of patients (Table 4B).
PROPENSITY WEIGHTED ANALYSIS
Sixty-five patients remained in the IPTW analysis. The correction
reduced part of the differences between the groups but was not
able to fully remove all differences (data not shown). Nevertheless,
with respect to the early endpoints defibrillation and CKMB/CK,
the differences between the groups became even more pronounced
after IPTW correction: the standardized difference increased from
−0.43 to −0.6 for the defibrillation factor, and from −0.74 to −1
for CKMB/CK, indicating a large biological difference between the
two groups.
DISCUSSION
Transplantation remains the current best option for patients suf-
fering end-stage heart failure. However, despite large efforts to
improve the rate of organ donation, the number of cardiac trans-
plantations annually performed has not really progressed over the
last two decades (11). Conversely, a continuously increasing num-
ber of patients are placed on a waiting list, a phenomenon that
may be explained by the aging of the population and the higher
proportion of patients surviving previous cardiac procedures, two
factors which may eventually lead to a growing number of patients
reaching terminal stages of cardiac insufficiency. Obviously, an
increase in the number of donor organs is urgently needed, but
development of strategies to further improve outcome of the recip-
ients of those grafts is as important and necessary. Mortality after
heart transplantation is still around 20, 30, and 50% after 3, 5,
and 10 years, respectively (11). But in fact, the steepest drop in
survival rate occurs during the first days or weeks following trans-
plantation, and has not changed much over the last decade (11).
In our current series, we also report on an early mortality rate
of 11 and 8% after 30 days in the Cardio− and Cardio+ groups,
respectively (p= ns). As in previous reports, early post-operative
mortality was mostly related to acute graft failure in our series
(7/8). Interestingly, two patients, both from the Cardio+ group,
survived the post-operative acute graft failure episode and their
actuarial follow-up period is 23.3 and 15.5 months, respectively.
Survival rate over the years was demonstrated to correlate
directly with the ischemic time of the graft (12–14). Especially
for ischemic times of 4 h or more, mid-term and long-term suc-
cess is severely compromised. This motivated the development and
now testing of organ perfusion systems, such as the Transmedics’
Organ Care System (the PROCEED II trial) or the Organ Trans-
port System’s LifeCradle, which may appear beneficial in regions
where distances between the organ procurement and implanta-
tion centers are too long to allow for ischemic times <240 min.
However, although promising, only little clinical experience has
been gathered so that the real benefit has not been proved yet. In
addition, technical requirements and costs may restrict applicabil-
ity. Conversely, repeating cardioplegia administration during the
ischemic period may represent a simple and attractive alternative.
In Switzerland, distances between centers are short and as such, it
is rare that the organ ischemic time is longer than 4 h (only one
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Table 1 | Characteristics of 81 HTx patients distributed in two groups depending on the use of additional cardioplegia.
Cardio− (without
additional cardioplegia)
Cardio+ (with
additional cardioplegia)
p-Value
(n=44) (n=37)
(A) RECIPIENTS
Females (%) 13 (30%) 13 (35%) 0.591
Age (years) 50.7±13.5 47.8±16.5 0.919
Age >60 (%) 13 (30%) 10 (27%) 0.802
Height (cm) 171.6±6.8 170.7±9.0 0.794
Weight (kg) 72.6±14.9 71.3±14.8 0.429
BSA (m2) 1.8±0.2 1.8±0.2 0.731
BMI (kg/m2) 24.6±4.5 24.4±4.3 0.888
Serum creatinine (preop, µmol/l) 124.0±63.0 132.2±82.6 0.919
Dialysis (preop, %) 4 (9%) 5 (14%) 0.440
Previous cardiac surgery (%) 27 (61%) 32 (86%) 0.011
Preoperative VAD/ICD (%) 32 (73%) 28 (76%) 0.763
EuroSCORE additive 12.2±4.1 9.4±3.2 0.068
EuroSCORE logistic 36.2±24.9 (30.5)a 20.5±15.8 (16.0)a 0.054
LVEF (%) 20.6±11.0 25.4±14.8 0.210
Urgency or emergency (%) 41 (93%) 32 (86%) 0.314
Dilatative cardiomyopathy (%) 39 (89%) 35 (95%) 0.342
Ischemic cardiomyopathy (%) 5 (11%) 2 (5%) 0.342
PHT (>150 dynes/s/cm5) 19 (43%) 11 (30%) 0.212
BNP 1541±2950 1167±2967 1.000
(B) DONORS
Females (%) 15 (34%) 12 (32%) 0.875
Age (years) 45.6±12.8 42.5±14.6 0.216
Age >60 (%) 4 (9%) 7 (19%) 0.198
Recipient and donor age >60 (%) 2 (5%) 6 (16%) 0.079
Female donor/male recipient (%) 9 (20%) 4 (11%) 0.239
Weight (kg) 76.9±10.1 76.0±12.6 0.919
Donor-recipient weight discrepancyb 0 (0%) 0 (0%) 1.0
Inotropes (%) 26 (59%) 24 (65%) 0.861
(C)TRANSPLANTATION
Graft ischemic time (min) 140±44 129±49 0.216
Organ ischemic time >180 min 10 (23%) 9 (24%) 0.866
Duration of surgery (min) 276±72 331±115 0.059
Duration of CPB (min) 139±35 157±46 0.150
Duration of reperfusion (min) 60±25 68±37 0.919
Duration of aortic cross-clamping of recipient (min) 64±17 82±31 0.150
BSA, body surface area, BMI, body mass index; VAD, ventricular assist device; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; PHT,
pulmonary hypertension; BNP brain-type natriuretic peptide.
aMedian.
bDonor weight is less than 30% of recipient’s weight.
patient in our series= 241 min). For the purpose of our analysis,
we therefore arbitrarily set a cut-off value to 3 h and observed that
survival was significantly better among patients who received a
supplementary dose of cardioplegia in situations where the organ
ischemic time was prolonged over 180 min. We can however not
determine how much this additional dose of cardioplegia did con-
tribute to the improved survival since a few other factors may also
have played a significant role regarding this positive evolution as
for instance the change in immunosuppression in 2007.
Dispensing an additional dose of crystalloid cardioplegia at
the time of implantation was not independently associated with a
better outcome, in terms of post-operative acute graft failure. Nev-
ertheless, the significant effect on several surrogates seems to indi-
cate that this strategy may have an additional protective effect and
may contribute to an overall improved post-operative evolution.
We observed, for instance, that the ratio of the cardiac enzymes
CK-MB/CK assessed during the first 24 h post-reperfusion was sig-
nificantly reduced in situations where an additional cardioplegic
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Table 2 | Post-operative course and incidence of complications.
Cardio− (without
additional cardioplegia)
Cardio+ (with
additional cardioplegia)
p-Value
(n=44) (n=37)
(A) IMMEDIATE POST-OP (24 h)
Defibrillation after aortic declamping (%) 21 (48%) 9 (24%) 0.030
CK (U/l) 617±317 901±470 0.003
CK-MB (U/l) 79±44 86±51 0.867
CK-MB/CK (%)b 13.3±4.2 (13.0)a 10.1±3.9 (9.5)a 0.001
High CK-MB/CK (>10%) 31 (70%) 16 (43%) 0.004
LDH (U/l)b 899±283 922±307 0.354
Chest tube drainage during initial six post-operative hours (ml) 704±1119 (405)a 501±538 (300)a 0.637
Chest tube drainage between 6 and 24 h post surgery (ml) 1485±2009 (875)a 1028±950 (709)a 0.637
Adrenaline during first six post-operative hours (µg/kg) 24.9±25.3 (18.2)a 21.2±19.0 (17.3)a 0.722
Adrenaline during first 24 h post surgery (µg/kg) 89.7±110.3 (59.3)a 83.2±71.5 (61.6)a 0.722
Noradrenaline during first six post-operative hours (µg/kg) 30.7±135.5 (4.1)a 6.6±10.1 (1.4)a 0.485
Noradrenaline during first 24 h post surgery (µg/kg) 37.2±144.9 (7.7)a 14.8±21.2 (2.9)a 0.903
High-dose vasopressor requirement during first 6 hc 11 (25%) 8 (22%) 0.554
High-dose vasopressor requirement during first 24 hc 7 (16%) 8 (22%) 0.569
Acute graft failure (%)d 4 (9%) 5 (14%) 0.528
Mortality at 24 h (%) 2 (2%) 2 (5%) 0.859
(B) EARLY EVOLUTION (IN-HOSPITAL AND/OR 30 DAYS)
ICU stay (days) 8.5±7.8 (4.9)a 3.9±2.1 (3.1)a 0.003
ICU >5 days (%) 20 (45%) 10 (27%) 0.073
Duration of intubation (days) 7.2±11.5 (2.6)a 2.0±1.6 (1.5)a 0.256
Intubation >48 h 23 (52%) 13 (35%) 0.123
Cumulative chest tube drainage (ml) 4720±6836 (2190)a 1897±1551 (1290)a 0.041
Adrenaline (cumulative, µg/kg) 376±1010 (154)a 177±162 (120)a 0.724
Noradrenaline (cumulative, µg/kg) 71.1±184.3 (11.8)a 24.5±32.6 (10.3)a 0.818
Serum creatinine (µmol/l) 238±142 240±125 0.917
New-onset renal insufficiency (%) 13 (30%) 11 (30%) 0.896
New-onset dialysis (%) 8 (18%) 2 (5%) 0.083
Re-exploration (bleeding) 6 (14%) 1 (3%) 0.082
Re-exploration (infection) 6 (14%) 1 (3%) 0.077
Rejection reaction (%) 9 (20%) 4 (11%) 0.243
Multiple organ failure (%) 3 (7%) 1 (3%) 0.399
Mortality at 30 days (%) 5 (11%) 3 (8%) 0.625
for ischemic time <180 min 1 2
for ischemic time >180 min 4 1
Conditional survivale 3/42 (7%) 1/35 (2.8%) 0.398
LDH, lactate dehydrogenase; ICU, intensive care unit.
aMedian.
bPeak value during the first 24 h.
c((Adrenaline µg/kg/min×100)+ (Noradrenaline µg/kg/min×100)+Dobutamine mg/kg/min(>10(10).
dDefined as the need for intra aortic balloon pump (IABP) and/or ECMO and/or VAD.
eWithout first 24 h mortality.
dose was administered, which may indicate improved myocardial
protection during the ischemic period (15–17). Also, the rate of
spontaneous return to sinus rhythm was significantly increased in
the Cardio+ group of patients, and may denote a better preserved
functional integrity of the cardiac muscle and/or conduction sys-
tem, as compared to the Cardio− group of grafts. Finally, although
the patients of both groups were in a similar preoperative condi-
tion, duration of intubation, ICU stay and post-operative duration
of hospitalization were significantly reduced, which implies faster
post-operative recovery.
In the current analysis, we chose to administer a new low-
volume (100 ml) cardioplegic crystalloid solution, Cardioplexol™.
This solution was developed in our institution, originally for
procedures performed with minimized extra-corporeal circuits
(MECC). Our experience with this type of cardioplegia on more
than 8000 patients, which has been only partially reported to date
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Table 3 | Long-term evolution.
Cardio−
(without
additional
cardioplegia)
Cardio+
(with
additional
cardioplegia)
p-Value
1-year mortality (%) 8 (18%) 3 (8%) 0.203
For ischemic time <180 min 3 2 0.809
for ischemic time >180 min 5 1 0.094
3-year mortality (%) 10 (23%) 4 (11%) 0.736
For ischemic time <180 min 5 3 0.785
For ischemic time >180 min 5 1 0.393
3-year EF (%) 62±5 62±5 0.777
3-year LVEDD (mm) 44±6 45±5 0.978
3-year LVESD (mm) 28±6 30±4 0.181
EF, ejection fraction; LVEDD, left ventricular end diastolic diameter; LVESD, left
ventricular end systolic diameter.
FIGURE 1 | Actuarial survival curves drawn for four subgroups defined
based on an organ ischemic period superior (>180) or inferior <180) to
180 min, and the instillation of supplemental cardioplegia before graft
implantation (Cardio+ or Cardio−). Patients who did not receive a
supplemental dose of cardioplegia had a significantly decreased survival
rate when ischemia was prolonged over 180 min (“Isch. >180; Cardio−” vs.
“Isch. >180; Cardio−”). It was also significantly decreased as compared to
patients who received a supplemental dose of cardioplegia (“Isch. >180;
Cardio−” vs. “Isch. >180; Cardio+”). Dotted lines represent the confidential
interval for the “Isch. >180; Cardio−” vs. “Isch. >180; Cardio+” groups.
(9), demonstrated several advantages over other more traditional
approaches, including an almost immediate cardiac arrest and a
prolongation of the cardioprotective effect over 45 min or more,
without the need to administer a second dose, and also minimal
hemodilution due to the reduced volume injected. The solution
is currently undergoing evaluation in a clinical phase 3 registra-
tion study in Europe (EudraCT Number 2011-004198-10). In the
current study, we chose this solution over others because of the
simplicity of its administration (two 50 ml syringes of the solu-
tion are slowly injected into both coronary ostia by the surgeon).
It remains to be proven whether similar results could have been
Table 4 | Endpoint post-operative acute graft failure: univariate
analysis (selection of data).
Acute graft failure p-Value
Yes No
(n=9) (n=72)
(A) DONOR
Organ ischemic time (min) 180±38 130±44 0.031
Organ Ischemic time >180 min (%) 5 (56%) 14 (19%) 0.016
Age >60 (%) 3 (33%) 8 (11%) 0.067
Recipient and Donor age >60 years (%) 3 (33%) 5 (7%) 0.012
Female (%) 6 (67%) 21 (29%) 0.024
(B) OPERATIVE DATA
Cross-clamp time (min) 78±24 72±26 0.455
Perfusion time (min) 213±48 139±32 0.004
Reperfusion time (min) 117±41 57±22 0.004
Operation time (min) 391±38 128±45 0.004
Only relevant parameters are presented. Detailed analysis is provided as
Appendix.
Table 5 | Endpoint post-operative assist device: logistic regression.
OR 95% CI p
Organ ischemic time >180 min 5.48 1.08–27.75 0.040
Donor gender (female) 5.84 1.13–33.01 0.035
Recipient and Donor age >60 (%) 6.33 0.86–46.75 0.070
Overall R2: 0.238; −2 log likelihood: −21.5; constant: 0.0037.
In an alternative analysis, OR (95% CI) for “organ ischemic time” entered as a
continuous variable (unit=minutes) was 1.031 (1.007–1.056; p=0.009).
reproduced with a different solution administered at the time of
implantation.
Obviously, our current study has limitations, and the results
must thus be interpreted with caution. The study is monocentric
and retrospective and the patients belonged to two consecutive
groups implying that other less measurable aspects, such as the
experience of the entire team, including anesthesiologists and
intensivists, may have played a role in improving our results dur-
ing the second period when additional cardioplegia was used. Also,
the relatively small number of patients is a limitation. Although
a series of risk factors may influence the occurrence of acute
graft rejection (such as the change of the post-operative mainte-
nance immunosuppression), the statistical analysis we performed
was restricted to a few parameters. In addition, the propensity
score could only partially compensate the difference between the
groups. Finally, and as already mentioned, the results obtained
with Cardioplexol™ may not be generalizable to other cardioplegic
solutions. Nevertheless, we believe the findings presented here are
hypothesis-generating, and will encourage further development
of protocols to improve cardioplegia in transplanted hearts. In
that sense, prospective randomized, ideally multicentric, studies
should be designed, especially since it might be that this simple
modification of a cardioplegia protocol represents an attractive
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and cost-effective alternative to the use of ex vivo organ perfusion
systems.
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APPENDIX
Table A1 | Characteristics of 81 HTx patients distributed in 2 groups
depending on the occurrence of post-operative acute graft failure.
Acute graft failure p-Value
Yes No
(n=9) (n=72)
(A) RECIPIENTS
Females (%) 4 (44%) 22 (31%) 0.400
Age (years) 49.5±16.2 49.3±14.9 0.969
Age >60 (%) 3 (33%) 20 (28%) 0.727
Size (cm) 168.2±5.0 171.5±8.1 0.119
Weight (kg) 71.4±9.9 72.1±15.3 0.969
BSA (m2) 1.8±0.1 1.8±0.2 0.969
BMI (kg/m2) 25.2±3.3 24.4±4.6 0.906
Serum creatinine (µmol/l) 153.3±43.8 124.5±74.7 0.146
Dialysis (%) 0 (0%) 9 (13%) 0.059
Previous cardiac surgery (%) 8 (89%) 51 (71%) 0.251
Preoperative VAD/ICD (%) 5 (56%) 55 (76%) 0.179
EuroSCORE additive 10.1±3.6 11.0±4.0 0.789
EuroSCORE logistic 24.4±20.1 29.6±22.9 0.968
LVEF (%) 21.1±7.0 23.0±13.6 0.644
Urgency or emergency (%) 7 (78%) 66 (92%) 0.363
Dilatative cardiomyopathy (%) 8 (89%) 66 (92%) 0.780
Ischemic cardiomyopathy (%) 1 (11%) 6 (8%) 0.780
PHT (>150 dynes/s/cm5) 33 (33%) 27 (38%) 0.807
BNP 635±365 1465±2995 1.000
(B) DONORS
Females (%) 6 (67%) 21 (29%) 0.024
Age (years) 46.6±17.5 43.9±13.2 0.969
Age >60 (%) 3 (33%) 8 (11%) 0.067
Weight (kg) 72.6±9.5 77.0±11.4 0.504
Recipient and donor age >60 (%) 3 (33%) 5 (7%) 0.012
Female donor/male recipient (%) 3 (33%) 10 (14%) 0.134
Weight <30% recipient (%) 0 (0%) 0 (0%)
Inotropes (%) 6 (67%) 44 (61%) 0.634
(C)TRANSPLANTATION
Organ ischemic time (min) 180±38 130±45 0.031
Organ ischemic time >180 min 5 (56%) 14 (19%) 0.016
Operation duration (min) 391±68 290±270 0.004
Perfusion time (min) 213±48 139±32 0.004
Reperfusion time (min) 117±41 57±22 0.004
Cross-clamp time (min) 78±24 72±26 0.455
BSA, body surface area, BMI, body mass index;VAD, left ventricular assist device;
ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction;
PHT, pulmonary hypertension; BNP, brain-type natriuretic peptide.
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